In addition, we performed a preliminary evaluation of the clinical safety of BCV in human subjects.<h4>Results</h4>BCV treatment significantly enhanced the infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells into the tumor immune microenvironment and promoted the secretion of anti-tumor effector molecules. The gene discussed is CD8A; the disease is neoplasm.